SCHEMBL23979366

SCHEMBL23979366

Cc1nc2ccc(Br)cc2c(=O)n1C1CCCC(=O)NC1=O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 7/20 0.62
CRBN Q96SW2 7/20 0.62
TNF P01375 1/20 0.50
IL1B P01584 1/20 0.50
IKZF3 Q9UKT9 1/20 0.50
GAA P10253 1/20 0.40
ALOX15 P16050 1/20 0.40
CASP3 P42574 2/20 0.39
CYP1A1 P04798 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP1B1 Q16678 1/20 0.39
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
ATM Q13315 2/20 0.38
MAPT P10636 1/20 0.38
LMNA P02545 1/20 0.38
HPGD P15428 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
PPARG P37231 1/20 0.38
CACNA2D1 P54289 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4098125 0.93 DDB1 (0.71) DDB1CRBNTNFIL1BIKZF3
SCHEMBL23979423 0.91 CRBN (0.62) DDB1CRBNTNFIL1BIKZF3
SCHEMBL23979373 0.87 CRBN (0.62) DDB1CRBNTNFIL1BIKZF3
SCHEMBL23979424 0.87 CRBN (0.62) DDB1CRBNTNFIL1BIKZF3
SCHEMBL23979593 0.87 DDB1 (0.62) DDB1CRBNTNFIL1BIKZF3
SCHEMBL28843218 0.84 DDB1 (0.47) DDB1CRBNTNFIL1BIKZF3
SCHEMBL31443763 0.84 CRBN (0.71) DDB1CRBNTNFIL1BIKZF3
SCHEMBL3650600 0.84 CRBN (0.71) DDB1CRBNTNFIL1BIKZF3
SCHEMBL23979419 0.84 DDB1 (0.59) DDB1CRBNTNFIL1BIKZF3
SCHEMBL23979477 0.83 DDB1 (0.67) DDB1CRBNTNFIL1BIKZF3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11773080-B2 Deuterium-enriched isoindolinonyl-azepanediones and related compounds and methods of treating medical disorders using same SALARIUS PHARMACEUTICALS, INC. (US) 2023-10-03 US disclosed
US-20210340125-A1 DEUTERIUM-ENRICHED ISOINDOLINONYL-AZEPANEDIONES AND RELATED COMPOUNDS AND METHODS OF TREATING MEDICAL DISORDERS USING SAME SALARIUS PHARMACEUTICALS, INC. 2021-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11773080-B2 Deuterium-enriched isoindolinonyl-azepanediones and related compounds and methods of treating medical disorders using same HPGDS, HPGD, AQP3 DDB1 690/4885CRBN 1079/4885TNF 2820/4885
US-20210340125-A1 DEUTERIUM-ENRICHED ISOINDOLINONYL-AZEPANEDIONES AND RELATED COMPOUNDS AND METHODS OF TREATING MEDICAL DISORDERS USING SAME HPGDS, HPGD, AQP3 DDB1 690/4885CRBN 1079/4885TNF 2820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.